DAVIS, Calif., April 30, 2018 -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, is pleased to announce that Grandevo CG® and Venerate CG®, have been approved for use on Cannabis by the Colorado, Nevada, and Washington Departments of Agriculture.
The active ingredients in Venerate CG and Grandevo CG bioinsecticides/miticides are each new species of non-living bacteria, with insecticidal and miticidal properties. Both products feature multiple modes of action that are complementary to one another. This complex activity makes the products excellent additions to insect and mite management programs, which allows the two products to be used on a standalone basis, or in conjunction in a rotational crop protection program. In addition, both products can be used right up to harvest and have the shortest re-entry period (4 hours). Cannabis growers have been adopting Venerate CG and Grandevo CG for control of spider mites, bud mites, thrips and aphids.
"Grandevo and Venerate are a game changer when it comes to IPM programs. I have eliminated all other preventive sprays and only use Grandevo and Venerate. I have had great results against all types of malicious bugs, from leaf eaters to root aphids these products have kept my gardens clean and my beneficial bugs happy,” said Kyle Stamback of Lean Cultivation, NorthWestGrown i502.
“We are pleased that the Colorado, Nevada and Washington Departments of Agriculture determined that Grandevo CG and Venerate CG meets their state’s criteria for use on Cannabis, and we look forward to working with growers and distributors to serve these exciting new markets with our existing product portfolio as well as our future innovations,” stated Lisa Malabad, Cannabis Segment Lead at Marrone Bio Innovations.
About Marrone Bio Innovations
Bio With Bite.
Marrone Bio Innovations, Inc. (NASDAQ:MBII) strives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. MBI’s effective and environmentally responsible pest management solutions help customers operate more sustainably while uniquely improving plant health and increasing crop yields. MBI’s currently available commercial products are Regalia®, Grandevo®, Venerate®, Majestene®, Haven® StargusTM and AmplitudeTM, ZeltoTM and Zequanox®. MBI also distributes Bio-tam 2.0® for Isagro USA and Jet-Ag® for Jet Harvest in most regions of the U.S.
Marrone Bio Innovations is dedicated to pioneering smart biopesticide solutions that support a better tomorrow for both farmers, turf managers and consumers around the globe. For more information, please visit www.marronebio.com.
Marrone Bio Innovations Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding the potential of Grandevo and Venerate CG and other MBI products in the Cannabis market, market projections, including the potential benefits of Grandevo and Venerate CG. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.
Marrone Bio Innovations Contacts:
Pam Marrone, CEO and Founder
Keith Pitts, Sr. VP of Regulatory and Government Affairs and Chief Sustainability Officer
Lisa Malabad, Product Marketing Manager and Cannabis Segment Lead
Telephone: +1 (530) 750-2800
Email: [email protected]
MBI Investor Relations:
Greg Falesnik
Managing Director
MZ Group – MZ North America
Main: 949-385-6449
[email protected]
www.mzgroup.us


Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
Same sparkle, different story: how lab-grown diamonds are transforming the market
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 



